Sanofi licenses regenerative osteoarthritis treatment from Scil
This article was originally published in Clinica
Executive Summary
Sanofi has exclusively licensed Scil Technology's preclinical stage programme for a regenerative treatment of osteoarthritis and cartilage disorders.